The role of rasagiline in the treatment of Parkinson’s disease
Julie Leegwater-Kim1, Elena Bortan21Tufts University School of Medicine and Department of Neurology, Lahey Clinic, Burlington, MA, USA; 2Department of Neurology, Lahey Clinic, Burlington, MA, USAAbstract: Parkinson’s disease (PD) is the second most common neurodegenerative disorder, affect...
Guardado en:
Autores principales: | Julie Leegwater-Kim, Elena Bortan |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8a3d0ef37dd64bfa898515d373301e9e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Role and clinical utility of pramipexole extended release in the treatment of early Parkinson's disease
por: Hametner EM, et al.
Publicado: (2012) -
EFFECT OF GAMMA-IRRADIATION ON BIODEGRADABLE MICROSPHERES LOADED WITH RASAGILINE MESYLATE
por: FERNÁNDEZ,MARCOS, et al.
Publicado: (2016) -
Levodopa in the treatment of Parkinson’s disease: an old drug still going strong
por: Werner Poewe, et al.
Publicado: (2010) -
Rasagiline for sleep disorders in patients with Parkinson’s disease: a prospective observational study
por: Schettino C, et al.
Publicado: (2016) -
Odor selectivity of hyposmia and cognitive impairment in patients with Parkinson’s disease
por: Mao CJ, et al.
Publicado: (2017)